Spots Global Cancer Trial Database for head and neck squamous cell cancer
Every month we try and update this database with for head and neck squamous cell cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) | NCT03975270 | Head and Neck S... | Sintilimab and ... | 18 Years - 70 Years | ChineseAMS | |
| Reactivating NK Cells in Treating Refractory Head and Neck Cancer | NCT02507154 | Nasopharyngeal ... Head and Neck S... | Cetuximab + NK ... | 21 Years - | National University Hospital, Singapore | |
| Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) | NCT02252042 | Head and Neck S... | Pembrolizumab Methotrexate Docetaxel Cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling | NCT02083692 | Head and Neck S... | Metformin | 18 Years - 80 Years | Thomas Jefferson University | |
| A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer | NCT04856631 | Head and Neck S... | Toripalimab Inj... Cetuximab Solut... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 | NCT03138070 | Head and Neck S... | BYL719 | 18 Years - | Lawson Health Research Institute | |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | NCT01351103 | Pancreatic Canc... BRAF Mutant Col... Melanoma Triple Negative... Head and Neck S... Cervical Squamo... Esophageal Squa... Lung Squamous C... | LGK974 PDR001 | 18 Years - | Novartis | |
| Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer | NCT00702481 | Head and Neck C... | Nimotuzumab Cisplatin Radiation | 21 Years - 70 Years | National Cancer Centre, Singapore | |
| Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer | NCT01790516 | Head and Neck S... | Cisplatin cetuximab Radiation | 18 Years - | Georgetown University | |
| Intensive Nutrition Counselling in Patients With Head and Neck Cancer | NCT02159508 | Head and Neck S... | Nutritional cou... | 18 Years - 80 Years | Helsinki University Central Hospital | |
| Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer | NCT03667482 | Head and Neck S... Recurrent Head ... Metastatic Head... | Cabozantinib Cetuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome | NCT03982537 | Head and Neck C... | N-Acetyl-L-Cyst... Chemotherapy an... | 18 Years - | Wake Forest University Health Sciences | |
| Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling | NCT02083692 | Head and Neck S... | Metformin | 18 Years - 80 Years | Thomas Jefferson University | |
| Head and Neck Cancer Screening and Serum Repository | NCT00592371 | Head and Neck S... | 18 Years - | University of Arkansas | ||
| Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer | NCT02485548 | Head and Neck S... | Raltitrexed 5-fluorouracil Cisplatin IMRT | 18 Years - 70 Years | Jiangsu Cancer Institute & Hospital | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| LITT and Pembrolizumab in Recurrent Brain Metastasis | NCT04187872 | Melanoma Non-small Cell ... Renal Cell Carc... Small-cell Lung... Head and Neck S... Classical Hodgk... Primary Mediast... Urothelial Carc... Microsatellite ... Gastric Cancer Esophageal Canc... Cervical Cancer Hepatocellular ... Merkel Cell Car... Brain Metastase... | LITT + Pembroli... | 18 Years - 100 Years | University of Florida | |
| Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer | NCT01326923 | Head and Neck S... | Cetuximab | 18 Years - | Louisiana State University Health Sciences Center Shreveport | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer | NCT00702481 | Head and Neck C... | Nimotuzumab Cisplatin Radiation | 21 Years - 70 Years | National Cancer Centre, Singapore | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | NCT06270706 | Metastatic Soli... | PLN-101095 Pembrolizumab | 18 Years - | Pliant Therapeutics, Inc. | |
| Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) | NCT02282371 | Head and Neck S... | Cetuximab BYL719 IMRT (Intensity... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) | NCT03975270 | Head and Neck S... | Sintilimab and ... | 18 Years - 70 Years | ChineseAMS | |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma | NCT02163057 | Head and Neck S... | INO-3112 CELLECTRA™-5P | 18 Years - | Inovio Pharmaceuticals | |
| LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer | NCT00260598 | Non-Small-Cell ... Head and Neck S... Pulmonary Disea... | LIFE Bronchosco... | 18 Years - 85 Years | University of Pittsburgh | |
| Intensive Nutrition Counselling in Patients With Head and Neck Cancer | NCT02159508 | Head and Neck S... | Nutritional cou... | 18 Years - 80 Years | Helsinki University Central Hospital | |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma | NCT02163057 | Head and Neck S... | INO-3112 CELLECTRA™-5P | 18 Years - | Inovio Pharmaceuticals | |
| Safety Study of Modified Vaccinia Virus to Cancer | NCT00574977 | Melanoma Breast Cancer Head and Neck S... Liver Cancer Colorectal Canc... Pancreatic Aden... | Vaccinia virus ... Vaccinia virus ... Vaccinia virus ... | 18 Years - | University of Pittsburgh | |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | NCT01351103 | Pancreatic Canc... BRAF Mutant Col... Melanoma Triple Negative... Head and Neck S... Cervical Squamo... Esophageal Squa... Lung Squamous C... | LGK974 PDR001 | 18 Years - | Novartis | |
| Intensive Nutrition Counselling in Patients With Head and Neck Cancer | NCT02159508 | Head and Neck S... | Nutritional cou... | 18 Years - 80 Years | Helsinki University Central Hospital | |
| A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 | NCT03138070 | Head and Neck S... | BYL719 | 18 Years - | Lawson Health Research Institute | |
| A Study of SGN-B6A in Advanced Solid Tumors | NCT04389632 | Carcinoma, Non-... Squamous Cell C... HER2 Negative B... Esophageal Squa... Esophageal Aden... Gastroesophagea... Ovarian Neoplas... Cutaneous Squam... Exocrine Pancre... Urinary Bladder... Uterine Cervica... Stomach Neoplas... | sigvotatug vedo... pembrolizumab cisplatin carboplatin | 18 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
